ReviewFrontiers in immunology2026
Autophagy modulation in gynaecologic oncology: insights into immune regulation and therapeutic potential.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a fundamental cellular process, autophagy maintains homeostasis and viability through the regulation of proteostasis, organelle quality control, and functional preservation. It represents the central pathway for transporting diverse cytoplasmic components to lysosomes for degradation and recycling. Accumulating evidence reveals the paradoxical role of autophagy in oncogenesis, where it can either suppress tumour development or facilitate cancer progression depending on context and stage. This conclusion is particularly evident during gynaecological tumour progression. Contemporary research priorities include deciphering the intricate involvement of autophagy in antitumour immunity and treatment resistance mechanisms. This comprehensive analysis systematically evaluates the dichotomous nature of autophagic processes across various malignancies and developmental phases, with a particular emphasis on how autophagy influences the dynamics of the gynaecological tumour microenvironment and modulates treatment responses. Key findings reveal that autophagy regulates immune checkpoint expression (e.g., PD-L1 and MHC-I); shapes antitumour immunity via T cells, macrophages, and other immune components; and modulates drug resistance through pathways involving AMP-activated protein kinase (AMPK), Heat shock factor 1 (HSF1), and Reactive oxygen species (ROS). These findings underscore the potential of autophagy as a therapeutic target and highlight strategies for combining autophagy modulators with conventional treatments to overcome resistance. This article provides a foundation for the development of precision medicine approaches tailored to autophagy-related pathways in gynaecologic malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.